Creative Enzymes introduces tumors and thromboembolism from six aspects, helping patients prevent and treat diseases. At the same time, Creative Enzymes provide enzymes for oncology and thrombus treatment.
Malignant tumor and VTE
VTE is one of the most important complications and major causes of death in cancer patients.
Malignant tumor is currently recognized as the acquired thrombophilia. VTE incidence of tumor patients is several times higher than that of general population.
Epidemiologic data of VTE in cancer patients
The incidence of venous thrombosis in patients with malignant tumors is as high as 3%-18%.
With all VTE patients, 20% are cancer patients; approximately 13% are treated with chemotherapy. Tumors cause 4.1 times higher in risk of thrombosis, while chemotherapy increases the risk of thrombosis in patients by 6.5 times.
Causes of "thrombophilia" in patients with tumor
Hypercoagulable state of the blood: the procoagulant substance increases and the anticoagulant decreases in the tumor patients. Tissue factor (TF) elevation is the main mechanism of hypercoagulability in tumor patients. Tumor cells activate platelets through many pathways and cause them thrombophilia. Antithrombin III, protein C, protein S and other anticoagulant substances decrease, which makes the body in a hypercoagulable state.
How can tumor patients be detected VTE early?
Improve VTE awareness and pay attention to clinical manifestations: when patients show swelling in lower limb, accelerated heart rate, dyspnea, unexplained fever and other suspicious symptoms or signs, they should promptly check VTE.
Prevention of VTE in tumor patients
Patients should do proper exercise and avoid long-term bed. When lying in the bed, they can raise the lower limbs to promote blood flow. For patients who are bedridden and suffer from active malignancy, low molecular weight heparin (LMWH), low dose unfractionated heparin (LDUH) or sulfonylurea may be recommended to prevent thrombosis without anticoagulation. For those with anticoagulant contraindications, intermittent pneumatic compression pump (IPC) or stretch stockings can be used for mechanical prevention of thrombosis.
Cancer treatment with VTE inpatients
Anticoagulant therapy: effectively reduce the risk of VTE and the probability of recurrence of thrombosis, which are the bases of thrombus treatment in the acute stage.
Thrombolytic therapy: for patients with a wide range of proximal acute DVT(Iliac femoral vein DVT, duration＜14d, good body function, expected survival≥1y), such as lower risk of bleeding, catheter thrombolysis is recommended.
Media Contact
Company Name: Creative Enzymes
Contact Person: Lisa Clara
Email:Send Email
Phone: 16316197922
Address:45-1 Ramsey Road
City: Shirley
State: New York 11967
Country: United States
Website: http://www.creative-enzymes.com
